Glycocalyx is the surface layer of endothelial cells, it lines the blood vessels and provides a cellular barrier against damage. Sulodexide has a protective effect on the glycocalyx and allows it to be rebuilt, and has anti-inflammatory, antioxidant, anticoagulant, and lipid profile-enhancing properties. Diabetic retinopathy damages the glycocalyx and vascular endothelium in the retina. Sulodexide rebuilds the glycocalyx and increases the integrity of the blood-retinal barrier, thereby protecting the retinal vasculature retina from hyperglycemia-induced damage. Clinical studies have confirmed that in non-proliferative diabetic retinopathy, sulodexide improves visual acuity, reduces microaneurysms and hard exudates. Further in a study evaluating recurrent retinal vein thrombosis, sulodexide reduced the recurrence rate. Sulodexide is a safe and well-tolerated drug and may play an important role in the treatment of diabetic retinopathy, both in reducing symptoms and improving visual function.
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.